News Releases

Tuesday, April 28, 2015

Nominations now open for 3rd annual Harrington Prize for Innovation in Medicine

CLEVELAND – National and international nominations are being sought for the third annual Harrington Prize for Innovation in Medicine, which honors a medical researcher for notable achievements in innovation, creativity and potential for clinical application. 
 
Deadline for nominations is August 28, 2015
Nomination guidelines can be found at:   HarringtonDiscovery.org/ThePrize
 
The Harrington Prize, which carries a $20,000 honorarium, is the result of a collaboration between The American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected medical honor societies, and the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development. The Harrington Discovery Institute is a nonprofit institute dedicated to enabling physician-scientists to transform their discoveries into therapies that enhance patient care. 


Wednesday, April 22, 2015

University Hospitals seeking participants for stress management study

CLEVELAND – The Connor Integrative Medicine Network at University Hospitals (UH) is seeking participants for a clinical research study to test whether stress management training can help lower blood pressure in people with pre-hypertension. A first-of-its-kind study, the Serenity Study is a collaboration between UH, Kent State University, and the University of Pennsylvania.
 
“Half of all adults in the U.S. have blood pressure that is too high, yet not high enough to be treated with medication,” says Francoise Adan, MD, Medical Director, Connor Integrative Medicine Network at UH and Assistant Professor of Psychiatry at Case Western Reserve University School of Medicine. “Most physicians recommend treating pre-hypertension with lifestyle changes such as improving diet, exercising and losing weight. We think that stress reduction training would help encourage these important lifestyle changes and may lower a patient’s blood pressure as well.” Dr. Adan is the principal investigator of the UH site.
 
Researchers are hoping to enroll 90 participants in the coming weeks. Eligible participants are non-smokers, between the ages 21 and 60, and not taking blood pressure medication. The program involves an eight-week group-based stress management class, each weekly session lasting about 2.5 hours, and one full-day stress management retreat. 


Monday, April 20, 2015

University Hospitals Honored with Booker T. Washington Award

WASHINGTON – Today the National Minority Quality Forum (NMQF) announced that University Hospitals (UH) in Cleveland, Ohio was the 2015 winner of the Booker T. Washington Award. Thomas F. Zenty III, Chief Executive Officer of UH, will accept the award during the annual NMQF Leadership Summit on Health Disparities and Congressional Black Caucus Spring Health Braintrust.
 
UH earned the award largely for the innovative ways it uses its civic and economic influence to create jobs and stimulate community vitality in Cleveland, especially in the neighborhoods around UH’s main campus on University Circle. This “anchor institution” work prompted the American Hospital Association to nominate UH.
 
“Our premise is straightforward: Health and wealth tend to go hand in hand,” Mr. Zenty said in accepting the honor. “Study after study demonstrate that people with jobs are more likely to use health care and be healthier. And research shows that unemployment has pronounced negative health consequences on working-age adults and their children. So at UH, we have consciously made a series of decisions to leverage our spending and our expertise to create jobs and help our community prosper.”


Friday, April 17, 2015

University Hospitals Geauga Medical Center performs first-ever prostate cancer treatment with new device

CLEVELAND – The radiation oncology team at UH Seidman Cancer Center at UH Geauga Medical Center performed the first-ever prostate cancer treatment on April 3 using a newly approved device. The device, called SpaceOAR® System, enhances the efficacy of radiation treatment by protecting organs surrounding the prostate. The device, a temporary injectable gel, received FDA clearance on April 1.
 
The “OAR” in SpaceOAR stands for “organ at risk.” Despite many advancements in radiation therapy for destroying prostate cancer cells, a common side-effect is damage to the rectum, which is located just below the prostate. Unintended radiation exposure due to their proximity often results in complications including diarrhea, bleeding and pain.
 
SpaceOAR, developed by Augmenix, Inc., temporarily positions the front portion of the rectum away from the prostate during radiation treatment, creating space for protection. The device uses hydrogel, which is administered in liquid form through a needle and quickly solidifies into a soft gel to separate the two organs. Potential benefits include the utilization of dose escalation (more prostate radiation for improved cancer kill rates) and hypofractionation (fewer radiation treatment sessions), both of which should have substantial patient benefits and help reduce healthcare costs.


Thursday, April 09, 2015

A downward trend for new cases of pediatric Melanoma

Cincinnati, OH, April 9, 2015 – Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years.  Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has been increasing. In a new study scheduled for publication in The Journal of Pediatrics, researchers found that the incidence of pediatric melanoma in the United States actually has decreased from 2004-2010.
 
Laura B. Campbell, MD, and colleagues from Case Western Reserve University and University Hospitals (UH) Case Medical Center in Cleveland, used data from the Surveillance, Epidemiology, and End Results cancer registries, which represent approximately 28% of the US population, to identify new cases of pediatric melanoma from 2000-2010.  According to Dr. Campbell, “We took an in-depth look at whether or not the number of new cases of melanoma per year in children and adolescents was increasing in the recent decade.”  They also studied how rates changed over time according to age, sex, type of melanoma, and its location on the body.
 
A total of 1,185 new cases of pediatric melanoma were identified.  Overall, the number of new cases each year decreased by 12% per year from 2004-2010. For boys, there was a decrease of almost 7% each year (2000-2010); in 15-19-year-olds, there was a decrease of 11% each year (2003-2010).  Additionally, new cases of pediatric melanoma located on the trunk and upper extremities, as well as cases with good prognostic indicators, both decreased significantly each year.



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.